Altius Direct Electrical Nerve Stimulation System
Neuros Medical, Inc. · Decision date Oct 16, 2026
What did the FDA decide?
The FDA record P230020/S011 shows a 30-day notice, decision OK30 dated 2026-10-16, for the Altius® Direct Electrical Nerve Stimulation System from Neuros Medical, Inc. The stated change is outsourcing insulator die-cutting activities and updating the associated dimensional tolerances. The supplement reason is filed as a process change affecting manufacturer, sterilizer, packager or supplier. This is a manufacturing supplement to PMA P230020, not a new approval of the whole system.
The supplied statement does not specify which die-cutting steps move to which supplier, what tolerance values changed, or what verification the applicant submitted. Its reported purpose is a process change; the notice itself does not demonstrate safety or clinical effectiveness, and no new indication or trial is implied. The device category field covers a totally implanted nerve terminus stimulator for chronic intractable post-amputation pain of the lower limb, product code SAZ.
FDA approval order statement
outsourcing insulator die-cutting activities and updating the associated dimensional tolerances
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Neurology
- Decision date
- Oct 16, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P230020/S011
- Regulatory pathway
- PMA supplement
- Applicant
- Neuros Medical, Inc.
- Product code
- SAZ
- Decision code
- OK30
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: stimulator, nerve terminus, totally implanted for chronic intractable post-amputation pain of the lower limb.
- Applicant
- Neuros Medical, Inc.
- Product code
- SAZ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230020. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230020 · Original PMA
Altius Direct Electrical Nerve Stimulation System
P230020/S011 received
Application receipt date recorded by FDA.
P230020/S011 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P230020. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230020
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Neuros Medical, Inc. | PMA approval | Aug 26, 2024 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Neuros Medical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 26800 Aliso Viejo Pkwy., Suite 250, Aliso Viejo, CA, 92656
Sources and methodology
- Original FDA record: P230020/S011
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records